← BioCryst Pharmaceuticals, Inc. (BCRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioCryst Pharmaceuticals, Inc. (BCRX)
Biological Products, (No Diagnostic Substances) · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
18
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BioCryst Pharmaceuticals (BCRX) is a commercial-stage rare disease biotech headquartered in Durham, NC, with 450 employees and a ~$2.4B market cap. The company generates revenue primarily from ORLADEYO (berotralstat), its approved oral HAE prophylaxis, which drove a dramatic revenue inflection from $271M in 2022 to $875M in 2025. The lead pipeline asset BCX7353 is in Phase 3 for HAE, and the company carries net debt of ~$224M against $172M cash representing roughly 8 months of runway.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BCX7353 | Phase 3 | Hereditary Angioedema (HAE) |
| Peramivir 200 mg | Phase 2 | Influenza |
| BCX4208 | Phase 2 | Gout |
| Oseltamivir | Phase 3 | Influenza |
| BCX7353 capsules | Phase 3 | Hereditary Angioedema, HAE |
| Forodesine 200 mg | Phase 2 | Cutaneous T-cell Lymphoma (CTCL), |
| ulodesine | Phase 2 | Gout |
| Peramivir | Phase 3 | Influenza |
| forodesine HCl | Phase 2 | Chronic Lymphocytic Leukemia (CLL) |
| Peramivir 150 mg | Phase 2 | Influenza |
| forodesine hydrochloride | Phase 2 | Lymphoma |
| BCX-1777 | Phase 2 | Leukemia, Lymphocytic |
| BCX4161 | Phase 3 | Hereditary Angioedema |
| forodesine hydrochloride (BCX-1777) | Phase 2 | Leukemia, T-Cell |
| Ulodesine (BCX4208) 5 mg | Phase 2 | Gout |
| Berotralstat | Phase 3 | Hereditary Angioedema |
| BCX9930 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
| Allopurinol | Phase 2 | Gout |
Price & technical context
3-month
-13.7%
6-month
-12.5%
12-month
+9.7%
52-wk range
$6.24–$11.11
vs 50-day MA
-10.2%
vs 200-day MA
-4.0%
Realized vol
48.0%
Max drawdown
-44.2%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BCRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.